Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy.

Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6018-22.

2.

Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface binding.

Annabi B, Currie JC, Bouzeghrane M, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R.

Biochem Biophys Res Commun. 2006 Jul 21;346(1):358-66. Epub 2006 Jun 2.

PMID:
16759641
3.

Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.

Annabi B, Bouzeghrane M, Currie JC, Dulude H, Daigneault L, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R.

Anticancer Drugs. 2006 Apr;17(4):429-38.

PMID:
16550001
4.

A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.

Nam RK, Reeves JR, Toi A, Dulude H, Trachtenberg J, Emami M, Daigneault L, Panchal C, Sugar L, Jewett MA, Narod SA.

J Urol. 2006 Apr;175(4):1291-7.

PMID:
16515983
5.

A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis.

Annabi B, Bouzeghrane M, Currie JC, Hawkins R, Dulude H, Daigneault L, Ruiz M, Wisniewski J, Garde S, Rabbani SA, Panchal C, Wu JJ, Béliveau R.

Clin Exp Metastasis. 2005;22(5):429-39.

PMID:
16283486
6.

Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer.

Hawkins RE, Daigneault L, Cowan R, Griffiths R, Panchal C, Armstrong A, Fenemore J, Irvine A, Sereda K, Dulude H.

Clin Prostate Cancer. 2005 Sep;4(2):91-9.

PMID:
16197609
7.

Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.

Gelmon KA, Latreille J, Tolcher A, Génier L, Fisher B, Forand D, D'Aloisio S, Vernillet L, Daigneault L, Lebecq A, Besenval M, Eisenhauer E.

J Clin Oncol. 2000 Dec 15;18(24):4098-108.

PMID:
11118471
8.

Cloning and identification of genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines.

Daigneault L, Beaulieu R, Filion M, Gaboury L, Royal A, Babaï F.

Clin Exp Metastasis. 1995 Sep;13(5):345-56.

PMID:
7543834
9.
10.

Two distinct pathways of interferon induction as revealed by 2-aminopurine.

Daigneault L, Haggarty A, Meng QH, Skup D.

Nucleic Acids Res. 1992 Jun 11;20(11):2749-54.

11.
12.

Stimulation of interferon beta gene transcription in vitro by purified NF-kappa B and a novel TH protein.

Cohen L, Lacoste J, Parniak M, Daigneault L, Skup D, Hiscott J.

Cell Growth Differ. 1991 Jul;2(7):323-33.

13.

An embryonic DNA-binding protein specific for a region of the human IFN beta 1 promoter.

Haggarty A, Ponton A, Paterno GD, Daigneault L, Skup D.

Nucleic Acids Res. 1988 Nov 25;16(22):10575-92.

14.

Presence of transcription regulatory elements within an intron of the virus-inducible murine TIMP gene.

Coulombe B, Ponton A, Daigneault L, Williams BR, Skup D.

Mol Cell Biol. 1988 Aug;8(8):3227-34.

15.

Regulation of interferon gene expression: mechanism of action of the If-1 locus.

Daigneault L, Coulombe B, Skup D.

J Virol. 1988 Apr;62(4):1125-31.

Supplemental Content

Loading ...
Support Center